Form 8-K - Current report:
SEC Accession No. 0001829126-25-001770
Filing Date
2025-03-14
Accepted
2025-03-14 06:00:26
Documents
19
Period of Report
2025-03-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cyclacel_8k.htm   iXBRL 8-K 38480
2 EXHIBIT 2.1 cyclacel_ex2-1.htm EX-2.1 302749
3 EXHIBIT 10.1 cyclacel_ex10-1.htm EX-10.1 97026
4 GRAPHIC img_001.jpg GRAPHIC 5777
5 GRAPHIC ex2-1_001.jpg GRAPHIC 3039
6 GRAPHIC ex10-1_001.jpg GRAPHIC 3039
  Complete submission text file 0001829126-25-001770.txt   723666

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE cycc-20250310.xsd EX-101.SCH 3744
8 XBRL DEFINITION FILE cycc-20250310_def.xml EX-101.DEF 26582
9 XBRL LABEL FILE cycc-20250310_lab.xml EX-101.LAB 36614
10 XBRL PRESENTATION FILE cycc-20250310_pre.xml EX-101.PRE 25206
21 EXTRACTED XBRL INSTANCE DOCUMENT cyclacel_8k_htm.xml XML 5625
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50626 | Film No.: 25737490
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)